PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Grandits et al., NCT05780541, NCT05780541

Feb 2024

Source PDF All Studies Meta AnalysisMeta

RCT 58 patients showing no significant differences with lufotrelvir. This is a 2021 study which has not been published yet. Results were made available on clinicaltrials.gov in 2024.

Important missing comments or errors? Let us know.

risk of death, 21.9% higher, RR 1.22, p = 0.77, treatment 9 of 32 (28.1%), control 6 of 26 (23.1%), day 90.

risk of no hospital discharge, 43.8% lower, RR 0.56, p = 0.11, treatment 9 of 32 (28.1%), control 13 of 26 (50.0%), NNT 4.6, day 90.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Grandits et al., 9 Feb 2024, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 1 author, trial NCT05780541 (history).

This Paper Lufotrelvir All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/​TICO Treatment Trial)

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)